

INFINITY PHARMACEUTICALS, INC.

Form 4

October 06, 2014

FORM 4**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
EVNIN ANTHONY B

(Last) (First) (Middle)

C/O INFINITY
PHARMACEUTICALS, INC, 780
MEMORIAL DRIVE

(Street)

CAMBRIDGE, MA 02139

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading
Symbol

INFINITY PHARMACEUTICALS,
INC. [INFI]

3. Date of Earliest Transaction
(Month/Day/Year)
10/03/2014

4. If Amendment, Date Original
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

☒ Director ☐ 10% Owner
☐ Officer (give title below) ☐ Other (specify below)

6. Individual or Joint/Group Filing(Check
Applicable Line)
☒ Form filed by One Reporting Person
☐ Form filed by More than One Reporting
Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V Amount (A) or (D) Price			
Common Stock	10/03/2014		M	6,000 A \$ 12.94	73,400	D	
Common Stock	10/03/2014		M	10,000 A \$ 12.94	83,400	D	
Common Stock	10/03/2014		M	7,500 A \$ 11.85	90,900	D	
Common Stock	10/03/2014		M	1,000 A \$ 11.85	91,900	D	

Edgar Filing: INFINITY PHARMACEUTICALS, INC. - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Amount or Number of Shares (Instr. 5)
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title		Amount or Number of Shares
Stock Option (Right to Buy)	\$ 12.94	10/03/2014		M	6,000	<u>(1)</u>	05/16/2022	Common Stock		6,000
Stock Option (Right to Buy)	\$ 12.94	10/03/2014		M	10,000	<u>(2)</u>	05/16/2022	Common Stock		10,000
Stock Option (Right to Buy)	\$ 11.85	10/03/2014		M	7,500	<u>(3)</u>	06/17/2024	Common Stock		7,500
Stock Option (Right to Buy)	\$ 11.85	10/03/2014		M	1,000	<u>(4)</u>	06/17/2024	Common Stock		1,000

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

EVNIN ANTHONY B
C/O INFINITY PHARMACEUTICALS, INC
780 MEMORIAL DRIVE
CAMBRIDGE, MA 02139

X

Signatures

/s/ Anthony B.
Evnin

10/03/2014

 **Signature of
Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) The options vested over a period of one year in equal quarterly installments beginning at the end of the first calendar quarter after the date of grant. As of the date hereof, the option had fully vested.
- (2) The options vested over a period of one year in equal quarterly installments beginning at the end of the first calendar quarter after the date of grant. As of the date hereof, the option had fully vested.
- (3) The options vested over a period of one year in equal quarterly installments beginning at the end of the first calendar quarter after the date of grant. As of the date hereof, the option had vested as to 7,500 shares subject to the option.
- (4) The options vested over a period of one year in equal quarterly installments beginning at the end of the first calendar quarter after the date of grant. As of the date hereof, the option had vested as to 1,000 shares subject to the option.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.